Serial Number
87278810
Owner
Titan Pharmaceuticals, Inc.Attorney
Jennifer Lee TaylorFirst Use Date
Feb 26, 2019
Filing Date
Dec 22, 2016
T Trademark
Serial Number: 87278810 • Registration: 5857855
Trademark Classes
Owner Contact Info
400 Oyster Point Boulevard, Suite 505
South San Francisco, CA 94080
Entity Type: 03
Legal Representation
Correspondence Address
JENNIFER LEE TAYLOR MORRISON & FOERSTER LLP
425 MARKET STREET
SAN FRANCISCO, CA 94105
UNITED STATES
Trademark Details
Filing Date
December 22, 2016
Registration Date
September 10, 2019
First Use Anywhere
February 26, 2019
First Use in Commerce
February 26, 2019
Published for Opposition
May 30, 2017
Cancellation Date
March 20, 2026
Goods & Services
Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
